id: NEW:stem_cell_therapy_access_to_NEW:non_malignant_disease_outcomes
name: Stem Cell Therapy Access â†’ Non-Malignant Disease Treatment Outcomes
from_node:
  node_id: NEW:stem_cell_therapy_access
  node_name: Stem Cell Therapy Access
to_node:
  node_id: NEW:non_malignant_disease_outcomes
  node_name: Non-Malignant Disease Treatment Outcomes
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Access to stem cell therapy programs enables patients with non-malignant,
  non-haematological diseases to receive advanced regenerative treatments'
- 'Step 2: Autologous stem cells (75% of cases) or allogenic stem cells (18%) are
  harvested primarily from bone marrow (51%), with alternatives including adipose
  tissue (7%) and other sources'
- 'Step 3: Stem cell transplantation promotes tissue regeneration and repair through
  cellular differentiation and paracrine effects in affected organs'
- 'Step 4: Clinical trials demonstrate safety and efficacy outcomes, with government
  research hospitals conducting majority of randomized controlled trials'
- 'Step 5: Successful stem cell engraftment and function leads to improved disease-specific
  outcomes across various non-malignant conditions'
evidence:
  quality_rating: A
  n_studies: 61
  primary_citation: 'Chandrashekhar Chavan et al. 2024. Stem cell therapy approaches
    for non-malignant diseases & non-haematological diseases in India: A systematic
    review. The Indian journal of medical research.'
  supporting_citations: []
description: Access to stem cell therapy for non-malignant diseases enables patients
  to receive regenerative treatments that can improve disease outcomes. A systematic
  review of 61 clinical studies in India (2001-2021) found predominantly autologous
  bone marrow-derived stem cell use across various non-haematological conditions.
  Government research hospitals conducted the majority of rigorous randomized trials,
  highlighting the importance of institutional capacity and regulatory oversight in
  ensuring safe and effective stem cell interventions.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: stem_cell_source
  direction: strengthens
  strength: moderate
  description: Bone marrow-derived stem cells (51%) were most commonly used, with
    autologous sources (75%) preferred over allogenic (18%) due to reduced rejection
    risk
- name: healthcare_facility_type
  direction: strengthens
  strength: moderate
  description: Government research hospitals conducted more randomized clinical trials
    with higher methodological standards compared to non-government facilities
- name: study_design_quality
  direction: strengthens
  strength: strong
  description: Randomized clinical trials with large sample sizes, control groups,
    and systematic adverse effect monitoring produce more reliable efficacy evidence
